Skip to main content

Aspira Women's Health Inc.

AWHL
Exchange
OTC
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0000926617

No open-market purchases or sales by Aspira Women's Health Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Aspira Women's Health Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of AWHL: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders9592−3
Shares31.0M29.8M−1.19M (−3.8%)
Value$174.1M$97.0M−$77.1M (−44.3%)

New holders (14)

Institutions that held Aspira Women's Health Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to AWHL in Q3 2021
InstitutionSharesValue% of portfolio
Marshall Wace, LLP91,798$298.0K0.00%
Alyeska Investment Group, L.P.75,392$245.0K0.00%
Citadel Advisors LLC65,997$215.0K0.00%
Engineers Gate Manager LP55,339$180.0K0.01%
Two Sigma Advisers, LP41,300$134.0K0.00%
Squarepoint Ops LLC27,218$88.0K0.00%
SG Americas Securities, LLC26,340$86.0K0.00%
Paloma Partners Management Co24,603$80.0K0.00%
Baker Tilly Wealth Management, LLC22,196$72.0K0.01%
Susquehanna Fundamental Investments, LLC17,256$56.0K0.00%
Macquarie Group Ltd15,092$49.0K0.00%
Balyasny Asset Management LLC10,366$34.0K0.00%
Envestnet Asset Management Inc10,157$33.0K0.00%
Rockefeller Capital Management L.P.1,000$3.00K0.00%

Sold out (17)

Institutions that held Aspira Women's Health Inc. at the end of Q2 2021 and filed for Q3 2021 without it.